Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesFRA:AOHA +5.22%48 Operating Margin % is -8.81% as of Mar. 2026. GuruFocus rates FRA:AOHA with a GF Score™ of 48/100 and a GF Value™ of €0.14 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 64.22% on this metric.
RUA Life Sciences PLC operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for RUA Life Sciences's Operating Margin % or its related term are showing as below:
FRA:AOHA'
s Operating Margin % Range Over the Past 10 Years
Min: -184.87 Med: -95.59 Max: -8.42
Current: -8.81
FRA:AOHA's Operating Margin % is ranked worse than 64.22% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.28
vs FRA:AOHA: -8.81
RUA Life Sciences's 5-Year Average Operating Margin % Growth Rate was 9.00% per year.
RUA Life Sciences (FRA:AOHA) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
RUA Life Sciences Operating Margin % Related Terms
RUA Life Sciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AOHA vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, RUA Life Sciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
RUA Life Sciences's Operating Margin % for the fiscal year that ended in Mar. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (FRA:AOHA) has a Operating Margin % of -8.81% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #524 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 64.2%.
Is RUA Life Sciences' Operating Margin % too high?
RUA Life Sciences' current Operating Margin % is -8.81%. Based on the distribution chart, RUA Life Sciences ranks #524 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #524 out of 816 companies for Operating Margin %. This places RUA Life Sciences in the lower half of its industry. The industry median Operating Margin % is 3.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.28, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Operating Margin % is -8.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (FRA:AOHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.14, compared to a current price of €0.24 — trading 72.9% above its estimated fair value. The current Operating Margin % is -8.81%. RUA Life Sciences' overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For RUA Life Sciences (FRA:AOHA), the current Operating Margin % is -8.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (FRA:AOHA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of €0.24 is trading 72.9% above its estimated GF Value™ of €0.14.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:AOHA:
Operating Margin %: -8.81%
GF Value™: €0.14 vs. price of €0.24 (72.9% above fair value)
No single metric tells the full story. See the FRA:AOHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
48GF Score
Get the complete analysis for FRA:AOHA
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AOHA has been successfully added to your 
